These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. Riddle MC; Drucker DJ Diabetes Care; 2006 Feb; 29(2):435-49. PubMed ID: 16443905 [No Abstract] [Full Text] [Related]
4. Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice. Parker JC; Lavery KS; Irwin N; Green BD; Greer B; Harriott P; O'Harte FP; Gault VA; Flatt PR J Endocrinol; 2006 Oct; 191(1):93-100. PubMed ID: 17065392 [TBL] [Abstract][Full Text] [Related]
5. [Effects of glucagon-like peptide 1 and its receptor agonist - liraglutide on cardiovascular system]. Gajos G; Stefański A; Gumprecht J Kardiol Pol; 2011; 69(7):709-16. PubMed ID: 21769795 [No Abstract] [Full Text] [Related]
6. [Beyond glycemic control in type 2 diabetes. Promises and gambles of therapy with glucagon-like peptide-1 receptor agonists]. Mannucci E G Ital Cardiol (Rome); 2011 Dec; 12(12 Suppl 2):3-4. PubMed ID: 22158420 [No Abstract] [Full Text] [Related]
7. Glucagon-Like Peptide 1 Analogs and their Effects on Pancreatic Islets. Tudurí E; López M; Diéguez C; Nadal A; Nogueiras R Trends Endocrinol Metab; 2016 May; 27(5):304-318. PubMed ID: 27062006 [TBL] [Abstract][Full Text] [Related]
8. Exenatide. From the Gila monster to you. Exenatide is the first of a new class of drugs known as "incretin mimetics" that can enhance your blood glucose control. Clark WL Diabetes Self Manag; 2006; 23(1):36, 39-40. PubMed ID: 16453919 [No Abstract] [Full Text] [Related]
9. Time course of cardiometabolic alterations in a high fat high sucrose diet mice model and improvement after GLP-1 analog treatment using multimodal cardiovascular magnetic resonance. Abdesselam I; Pepino P; Troalen T; Macia M; Ancel P; Masi B; Fourny N; Gaborit B; Giannesini B; Kober F; Dutour A; Bernard M J Cardiovasc Magn Reson; 2015 Nov; 17():95. PubMed ID: 26546347 [TBL] [Abstract][Full Text] [Related]
10. Pharmacological Actions of Glucagon-Like Peptide-1, Gastric Inhibitory Polypeptide, and Glucagon. Sekar R; Singh K; Arokiaraj AW; Chow BK Int Rev Cell Mol Biol; 2016; 326():279-341. PubMed ID: 27572131 [TBL] [Abstract][Full Text] [Related]
13. Bariatric surgery and the gut-brain communication--the state of the art three years later. Diniz Mde F; Azeredo Passos VM; Diniz MT Nutrition; 2010 Oct; 26(10):925-31. PubMed ID: 20392599 [TBL] [Abstract][Full Text] [Related]
18. GLP-1 and Amylin in the Treatment of Obesity. Jorsal T; Rungby J; Knop FK; Vilsbøll T Curr Diab Rep; 2016 Jan; 16(1):1. PubMed ID: 26699764 [TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptides 1 and 2 in health and disease: a review. Marathe CS; Rayner CK; Jones KL; Horowitz M Peptides; 2013 Jun; 44():75-86. PubMed ID: 23523778 [TBL] [Abstract][Full Text] [Related]
20. Gila monster's guide to surgery for obesity and diabetes. Mason EE J Am Coll Surg; 2008 Feb; 206(2):357-60. PubMed ID: 18222392 [No Abstract] [Full Text] [Related] [Next] [New Search]